Literature DB >> 25092223

Possible role of fibroblast growth factor 21 on atherosclerosis via amelioration of endoplasmic reticulum stress-mediated apoptosis in apoE(-/-) mice.

Xi Wu1,2, Yong-Fen Qi3,4, Jin-Rui Chang3, Wei-Wei Lu3, Jin-Sheng Zhang3, Shao-Ping Wang5, Shu-Juan Cheng5, Ming Zhang5, Qian Fan5, Yuan Lv5, Hui Zhu5, Man-Kun Xin5, Yun Lv5, Jing-Hua Liu6.   

Abstract

Fibroblast growth factor 21 (FGF-21) is an endocrine factor that can be secreted into circulation by the liver. FGF-21 takes part in metabolic actions and is thought to be a promising candidate for the treatment of diabetes. However, the role of FGF-21 in atherosclerosis is unknown. In this study, apoE(-/-) mice were fed an atherogenic diet for 4 weeks with and without subcutaneous injections of FGF-21. ApoE(-/-) mice fed an atherogenic diet showed hyperlipidemia, a large plaque area in aortas and increased vessel wall thickness. Plasma FGF-21 content and protein level of FGF receptor 1 (FGFR1) in aortas was greater in apoE(-/-) than C57BL/6J mice. Exogenous FGF-21 treatment significantly ameliorated dyslipidemia in apoE(-/-) mice. FGF-21-treated apoE(-/-) mice showed reduced number of aortic plaques and plaque area as well as reduced number of TUNEL-positive cells. Protein levels of the endoplasmic reticulum stress markers glucose-regulated protein 94, caspase-12 and C/EBP homologous protein were reduced by 34.5, 31.4 and 26.5 %, respectively, in apoE(-/-) mice. Endogenous expression of FGF-21 and its receptor FGFR1 were upregulated in apoE(-/-) mice, and exogenous administration of FGF-21 ameliorated the atherogenic-induced dyslipidemia and vascular atherosclerotic lesions. FGF-21 protecting against atherosclerosis might be in part by its inhibitory effects on endoplasmic reticulum stress-mediated apoptosis.

Entities:  

Keywords:  Apoptosis; Atherosclerosis; Endoplasmic reticulum stress; Fibroblast growth factor 21

Mesh:

Substances:

Year:  2014        PMID: 25092223     DOI: 10.1007/s00380-014-0557-9

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  48 in total

1.  Fibroblast growth factor 21 as a possible endogenous factor inhibits apoptosis in cardiac endothelial cells.

Authors:  Yun Lü; Jing-Hua Liu; Li-Ke Zhang; Jie DU; Xiang-Jun Zeng; Gang Hao; Ji Huang; Dong-Hui Zhao; Guo-Zhong Wang; Ying-Chuan Zhang
Journal:  Chin Med J (Engl)       Date:  2010-12       Impact factor: 2.628

2.  Adrenomedullin ameliorates the development of atherosclerosis in apoE-/- mice.

Authors:  Chun Shui Pan; Jing Zhang; Fang Yu; Xu Teng; Chang Qi Cao; Wei Wu; Chao Shu Tang; Yong Fen Qi
Journal:  Peptides       Date:  2010-03-21       Impact factor: 3.750

Review 3.  Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: the importance of lesion stage and phagocytic efficiency.

Authors:  Ira Tabas
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-09-01       Impact factor: 8.311

Review 4.  GRP94 in ER quality control and stress responses.

Authors:  Davide Eletto; Devin Dersh; Yair Argon
Journal:  Semin Cell Dev Biol       Date:  2010-03-16       Impact factor: 7.727

Review 5.  Phagocytosis in atherosclerosis: Molecular mechanisms and implications for plaque progression and stability.

Authors:  Dorien M Schrijvers; Guido R Y De Meyer; Arnold G Herman; Wim Martinet
Journal:  Cardiovasc Res       Date:  2006-09-16       Impact factor: 10.787

6.  Serum fibroblast growth factor 21 is associated with renal function and chronic kidney disease in community-dwelling adults.

Authors:  Candace Crasto; Richard D Semba; Kai Sun; Luigi Ferrucci
Journal:  J Am Geriatr Soc       Date:  2012-04       Impact factor: 5.562

7.  In vivo induction of endothelial apoptosis leads to vessel thrombosis and endothelial denudation: a clue to the understanding of the mechanisms of thrombotic plaque erosion.

Authors:  E Durand; A Scoazec; A Lafont; J Boddaert; A Al Hajzen; F Addad; M Mirshahi; M Desnos; A Tedgui; Z Mallat
Journal:  Circulation       Date:  2004-05-17       Impact factor: 29.690

Review 8.  ER stress in cardiovascular disease.

Authors:  Tetsuo Minamino; Masafumi Kitakaze
Journal:  J Mol Cell Cardiol       Date:  2009-11-12       Impact factor: 5.000

9.  PPARalpha is a key regulator of hepatic FGF21.

Authors:  Thomas Lundåsen; Mary C Hunt; Lisa-Mari Nilsson; Sabyasachi Sanyal; Bo Angelin; Stefan E H Alexson; Mats Rudling
Journal:  Biochem Biophys Res Commun       Date:  2007-06-21       Impact factor: 3.575

Review 10.  Stress management at the ER: regulators of ER stress-induced apoptosis.

Authors:  Adrienne M Gorman; Sandra J M Healy; Richard Jäger; Afshin Samali
Journal:  Pharmacol Ther       Date:  2012-02-17       Impact factor: 12.310

View more
  21 in total

Review 1.  Fibroblast growth factor 21 in chronic kidney disease.

Authors:  Paulo Giovanni de Albuquerque Suassuna; Rogério Baumgratz de Paula; Hélady Sanders-Pinheiro; Orson W Moe; Ming-Chang Hu
Journal:  J Nephrol       Date:  2018-11-14       Impact factor: 3.902

2.  Aortic smooth muscle cell alterations in mice systemically exposed to arsenic.

Authors:  Shih-Chieh Chen; Shin-Yin Huang; Wen-Ting Lin; Rei-Cheng Yang; Hsin-Su Yu
Journal:  Heart Vessels       Date:  2015-07-02       Impact factor: 2.037

3.  The relationship of circulating fibroblast growth factor 21 levels with incident atrial fibrillation: The Multi-Ethnic Study of Atherosclerosis.

Authors:  Tsz Him Hui; Robyn L McClelland; Matthew A Allison; Carlos J Rodriguez; Richard A Kronmal; Susan R Heckbert; Erin D Michos; Philip J Barter; Kerry-Anne Rye; Kwok Leung Ong
Journal:  Atherosclerosis       Date:  2017-12-25       Impact factor: 5.162

Review 4.  Fibroblast growth factor 21: a regulator of metabolic disease and health span.

Authors:  Ting Xie; Po Sing Leung
Journal:  Am J Physiol Endocrinol Metab       Date:  2017-05-30       Impact factor: 4.310

Review 5.  The roles of FGF21 in atherosclerosis pathogenesis.

Authors:  Farzane Shanebandpour Tabari; Ansar Karimian; Hadi Parsian; Vahid Rameshknia; Ata Mahmoodpour; Maryam Majidinia; Mahmood Maniati; Bahman Yousefi
Journal:  Rev Endocr Metab Disord       Date:  2019-03       Impact factor: 6.514

6.  Naringenin ameliorates hypoxia/reoxygenation-induced endoplasmic reticulum stress-mediated apoptosis in H9c2 myocardial cells: involvement in ATF6, IRE1α and PERK signaling activation.

Authors:  Jia-You Tang; Ping Jin; Qing He; Lin-He Lu; Ji-Peng Ma; Wei-Lun Gao; He-Ping Bai; Jian Yang
Journal:  Mol Cell Biochem       Date:  2016-10-26       Impact factor: 3.396

Review 7.  Adipokines, adiposity, and atherosclerosis.

Authors:  Longhua Liu; Zunhan Shi; Xiaohui Ji; Wenqian Zhang; Jinwen Luan; Tarik Zahr; Li Qiang
Journal:  Cell Mol Life Sci       Date:  2022-05-03       Impact factor: 9.261

8.  Serum fibroblast growth factor 21 levels is associated with lower extremity atherosclerotic disease in Chinese female diabetic patients.

Authors:  Xiaoyan Zhang; Yanyun Hu; Hui Zeng; Lianxi Li; Jungong Zhao; Jun Zhao; Fang Liu; Yuqian Bao; Weiping Jia
Journal:  Cardiovasc Diabetol       Date:  2015-03-11       Impact factor: 9.951

Review 9.  Implication of hepatokines in metabolic disorders and cardiovascular diseases.

Authors:  Tae Woo Jung; Hye Jin Yoo; Kyung Mook Choi
Journal:  BBA Clin       Date:  2016-03-05

10.  Mesenchymal Stem Cells Stabilize Atherosclerotic Vulnerable Plaque by Anti-Inflammatory Properties.

Authors:  Shuang-shuang Wang; Si-wang Hu; Qing-hua Zhang; Ai-xiang Xia; Zhi-xin Jiang; Xiao-min Chen
Journal:  PLoS One       Date:  2015-08-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.